Dalibor Sedlacek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9436966/publications.pdf

Version: 2024-02-01

20 papers

596 citations

1039880 9 h-index 18 g-index

20 all docs

20 docs citations

times ranked

20

1104 citing authors

#	Article	IF	CITATIONS
1	The Presence of Either Typical or Atypical Radiological Changes Predicts Poor COVID-19 Outcomes in HIV-Positive Patients from a Multinational Observational Study: Data from Euroguidelines in Central and Eastern Europe Network Group. Viruses, 2022, 14, 972.	1.5	3
2	Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test. Diagnostics, 2021, 11, 593.	1.3	24
3	Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection. Diagnostics, 2021, 11, 1915.	1.3	1
4	Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons. Aids, 2020, 34, 1485-1495.	1.0	3
5	People who inject drugs remain hard-to-reach population across all HIV continuum stages in Central, Eastern and South Eastern Europe $\hat{a}\in \hat{b}$ data from Euro-guidelines in Central and Eastern Europe Network. Infectious Diseases, 2019, 51, 277-286.	1.4	20
6	Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 10-17.	0.9	13
7	HIV care in Central and Eastern Europe: How close are we to the target?. International Journal of Infectious Diseases, 2018, 70, 121-130.	1.5	37
8	Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial. Clinical Infectious Diseases, 2018, 67, 420-429.	2.9	18
9	Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. Aids, 2018, 32, 205-215.	1.0	5
10	Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations. Aids, 2018, 32, 2807-2819.	1.0	13
11	Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. Clinical Infectious Diseases, 2017, 64, 1413-1421.	2.9	66
12	Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death. PLoS ONE, 2017, 12, e0166613.	1.1	2
13	Risk Factors for Low Immune Recovery Among Participants with CD4+ Counts > 500 cells/mm3 who Achieved Viral Suppression in the Immediate Antiretroviral Treatment (ART) Group in Strategic Timing of Antiretroviral Treatment (START) Trial. Open Forum Infectious Diseases, 2016, 3, .	0.4	O
14	CNS-related mortality in HIV-1 infected persons in the Czech Republic. Journal of the Neurological Sciences, 2015, 357, e210-e211.	0.3	0
15	Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death. Journal of the International AIDS Society, 2014, 17, 19685.	1.2	1
16	Histamine increases the level of IFN \hat{i}^3 produced by HIV-1 specific CTLs and this production depends on total IgE level. Journal of Immunological Methods, 2012, 375, 1-6.	0.6	6
17	A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Medicine, 2011, 12, 259-268.	1.0	19
18	Prevalence of Human Leukocyte Antigen (HLA)-B*5701 in HIV-infected Subjects in Czech Republic. Central European Journal of Public Health, 2011, 19, 128-130.	0.4	2

#	Article	IF	CITATIONS
19	Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. Aids, 2010, 24, 1667-1678.	1.0	353
20	Seven Antiphospholipid Antibodies in HIV-Positive Patients: Correlation with Clinical Course and Laboratory Findings. American Journal of Reproductive Immunology, 2003, 50, 439-443.	1.2	10